[Monthly prevalence of generalized anxiety disorder during the Covid-19 pandemic in Mexico]. / Prevalencia mensual de trastorno de ansiedad generalizada durante la pandemia por Covid-19 en México.

Objective. Estimate the prevalence of generalized anxiety disorder (GAD) from April to June 2020. Materials and methods. Repeated cross-sections design based in the Encovid-19, a series of monthly mobile surveys with representative samples of Mexico (N= 833-1 674). The questionnaire includes the GAD-2 scale, and, in July, the GAD-7 scale was added; we examined its internal validity with confirmatory factor analysis and its concurrent validity with sociodemographic variables. Using GAD-7 as criterion, we analyzed the predictive validity of the GAD-2. We estimated the monthly prevalence with the GAD-2. Results. The GAD-7 and the GAD-2 are reliable and valid. The GAD-2 has a sensitivity of 0.87 and a specificity of 0.90. The monthly prevalence remains high and stable, between 30.7 and 32.6%. GAD concentrated in women, unemployed and persons with low socioeconomic status. Conclusions. GAD is a public health problem that worsened during the Covid-19 pandemic.

Monthly prevalence of generalized anxiety disorder during the COVID-19 pandemic in Mexico (preprint)

AbstractObjective: Estimate the prevalence of generalized anxiety disorder (GAD) from April to June 2020. Methods: Repeated cross-sections design based in the ENCOVID-19 – a series of monthly mobile surveys with representative samples of Mexico (N= 833- 1,674). The questionnaire includes the GAD-2 scale, and, in July, the GAD-7 scale was added; we examined its internal validity with confirmatory factor analysis and its concurrent validity with sociodemographic variables. Using GAD-7 as criterion, we analyzed the predictive validity of the GAD-2. We estimated the monthly prevalence with the GAD-2. Results: The GAD-7 and the GAD-2 are reliable and valid. The GAD-2 has a sensitivity of 0.87 and a specificity of 0.90. The monthly prevalence remains high and stable, between 30.7 and 32.6%. GAD concentrated in women, unemployed and persons with low socioeconomic status. Conclusions: GAD is a public health problem that worsened during the COVID-19 pandemic. Resumen Objetivo: Estimar la prevalencia de ansiedad generalizada (GAD) entre abril y junio de 2020. Material y Métodos: Diseño transversal repetido basado en la ENCOVID-19 –serie de encuestas telefónicas mensuales con muestras representativas de México (N= 833- 1,674). El cuestionario incluye la escala GAD-2 y en julio se añadió la GAD-7; se examinó su validez interna con análisis factorial confirmatorio y su validez concurrente con variables sociodemográficas. Con la GAD-7 como criterio, se calculó la validez predictiva de la GAD-2. Se estimó la prevalencia mensual con la GAD-2. Resultados: La GAD-7 y la GAD-2 son confiables y válidas. La GAD-2 tiene una sensibilidad de 0.87 y una especificidad de 0.90. La prevalencia mensual se mantuvo alta y estable, entre 30.7 y 32.6%. El GAD se concentró en mujeres, personas desocupadas y de bajo nivel socioeconómico. Conclusiones: El GAD es un problema de salud pública que se agravó con la pandemia por COVID-19.